The past and future of haemophilia: diagnosis, treatments, and its complications

The Lancet

Volumn 388, Issue 10040, 2016, Pages 187-197

  Peyvandi, Flora ^a,b   Garagiola, Isabella ^b   Young, Guy ^c,d  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 8; COAGULATING AGENT; NEUTRALIZING ANTIBODY;

BLOOD TRANSFUSION; CLINICAL FEATURE; COMPLICATION; GENE THERAPY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; MOLECULAR DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SCREENING TEST; SUBSTITUTION THERAPY; TREATMENT INDICATION; EARLY INTERVENTION; HEMORRHAGE; IMMUNOLOGY;

ANTIBODIES, NEUTRALIZING; COAGULANTS; EARLY MEDICAL INTERVENTION; FACTOR IX; FACTOR VIII; GENETIC THERAPY; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS;

EID: 84958580623     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)01123-X     Document Type: Review

References (141)

1. 1 Mannucci, PM, Tuddenham, EG, The hemophilias—from royal genes to gene therapy. N Engl J Med 344 (2001), 1773–1779.
2. 2 Rosendaal, FR, Briët, E, The increasing prevalence of haemophilia. Thromb Haemost, 63, 1990, 145.
3. 3 Kamal, AH, Tefferi, A, Pruthi, RK, How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82 (2007), 864–873.
4. 4 White, GC 2nd, Rosendaal, F, Aledort, LM, Lusher, JM, Rothschild, C, Ingerslev, J, Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost, 85, 2001, 560.
5. 5 Attard, C, van der Straaten, T, Karlaftis, V, Monagle, P, Ignjatovic, V, Developmental hemostasis: age-specific differences in the levels of hemostatic proteins. J Thromb Haemost 11 (2013), 1850–1854.
6. 6 Chandler, WL, Ferrell, C, Lee, J, Tun, T, Kha, H, Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol 120 (2003), 34–39.
7. 7 Barrowcliffe, TW, Monitoring haemophilia severity and treatment: new or old laboratory tests?. Haemophilia 10:suppl 4 (2004), 109–114.
8. 8 Santagostino, E, Mancuso, ME, Tripodi, A, et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 8 (2010), 737–743.
9. 9 Oldenburg, J, Pavlova, A, Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 30 (2010), 207–211.
10. 10 Pavlova, A, Delev, D, Pezeshkpoor, B, Müller, J, Oldenburg, J, Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thromb Haemost 111 (2014), 851–861.
11. 11 Chalmers, E, Williams, M, Brennand, J, et al. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 154 (2011), 208–215.
12. 12 Barrowcliffe, TW, Standardization of FVIII & FIX assays. Haemophilia 9 (2003), 397–402.
13. 13 Gouw, SC, van den Berg, HM, Oldenburg, J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119 (2012), 2922–2934.
14. 14 Lakich, D, Kazazian, HH Jr, Antonarakis, SE, Gitschier, J, Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 5 (1993), 236–241.
15. 15 Bagnall, RD, Waseem, N, Green, PM, Giannelli, F, Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe haemophilia A. Blood 99 (2002), 168–174.
16. 16 Lannoy, N, Abinet, I, Dahan, K, Hermans, C, Identification of de novo deletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency. Haemophilia 15 (2009), 797–880.
17. 17 Oldenburg, J, Ivaskevicius, V, Rost, S, et al. Evaluation of DHPLC in the analysis of hemophilia A. J Biochem Biophys Methods 47 (2001), 39–51.
18. 18 Jayandharan, G, Shaji, RV, Baidya, S, Nair, SC, Chandy, M, Srivastava, A, Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia 11 (2005), 481–491.
19. 19 Vinciguerra, C, Zawadzki, C, Dargaud, Y, et al. Characterisation of 96 mutations in 128 unrelated severe haemophilia A patients from France. Description of 62 novel mutations. Thromb Haemost 95 (2006), 593–599.
20. 20 Bogdanova, N, Markoff, A, Eisert, R, Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A. Hum Mutat 28 (2007), 54–60.
21. 21 Santacroce, R, Acquila, M, Belvini, D, et al. Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with hemophilia A. J Hum Genet 53 (2008), 275–284.
22. 22 El-Maarri, O, Herbiniaux, U, Graw, J, et al. Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene. J Thromb Haemost 3 (2005), 332–339.
23. 23 Casana, P, Haya, S, Cid, AR, et al. Identification of deletion carriers in hemophilia B: quantitative real-time polymerase chain reaction or multiple ligation probe amplification. Transl Res 153 (2009), 114–117.
24. 24 Funnell, AP, Wilson, MD, Ballester, B, et al. A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden. Am J Hum Genet 92 (2013), 460–467.
25. 25 Funnell, AP, Crossley, M, Hemophilia B Leyden and once mysterious cis-regulatory mutations. Trends Genet 30 (2014), 18–23.
26. 26 Crossley, M, Ludwig, M, Stowell, KM, De Vos, P, Olek, K, Brownlee, GG, Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 257 (1992), 377–379.
27. 27 Ljung, R, Petrini, P, Tengborn, L, Sjörin, E, Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 113 (2001), 81–86.
28. 28 Tagariello, G, Belvini, D, Salviato, R, et al. The Italian haemophilia B mutation database: a tool for genetic counselling, carrier detection and prenatal diagnosis. Blood Transfus 5 (2007), 158–163.
29. 29 Goodeve, AC, Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost 13 (2015), 1184–1195.
30. 30 Thompson, AR, Bajaj, SP, Chen, SH, MacGillivray, RT, ‘Founder’ effect in different families with haemophilia B mutation. Lancet, 335, 1990, 418.
31. 31 Jenkins, PV, Egan, H, Keenan, C, et al. Mutation analysis of haemophilia B in the Irish population: increased prevalence caused by founder effect. Haemophilia 14 (2008), 717–722.
32. 32 Peyvandi, F, Kunicki, T, Lillicrap, D, Genetic sequence analysis of inherited bleeding diseases. Blood 122 (2013), 3423–3431.
33. 33 Tabor, A, Vestergaard, CH, Lidegaard, Ø, Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol 34 (2009), 19–24.
34. 34 Lo, YM, Corbetta, N, Chamberlain, PF, et al. Presence of foetal DNA in maternal plasma and serum. Lancet 350 (1997), 485–487.
35. 35 Devaney, SA, Palomaki, GE, Scott, JA, Bianchi, DW, Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 306 (2011), 627–636.
36. 36 Mortarino, M, Garagiola, I, Lotta, LA, Siboni, SM, Semprini, AE, Peyvandi, F, Non-invasive tool for foetal sex determination in early gestational age. Haemophilia 17 (2011), 952–956.
37. 37 Sermon, K, Van Steirteghem, A, Liebaers, I, Preimplantation genetic diagnosis. Lancet 363 (2004), 1633–1641.
38. 38 Peyvandi, F, Garagiola, I, Mortarino, M, Prenatal diagnosis and preimplantation genetic diagnosis: novel technologies and state of the art of PGD in different regions of the world. Haemophilia 17:suppl 1 (2011), 14–17.
39. 39 Nagel, K, Walker, I, Decker, K, Chan, HKC, Pai, MK, Comparing bleed frequency and factor concentrate use between haemophilia A and haemophilia B. Haemophilia 17 (2011), 872–874.
40. 40 Santagostino, E, Fasulo, MR, Hemophilia A and hemophilia B: different types of diseases?. Semin Thromb Hemost 39 (2013), 697–701.
41. 41 Clausen, N, Petrini, P, Claeyssens-Donadel, S, Gouw, SC, Liesner, R, PedNet and Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A and B: a cohort study. Haemophilia 20 (2014), 747–755.
42. 42 Kulkarni, R, Lusher, J, Perinatal management of neonates with haemophilia. Br J Haematol 112 (2001), 264–274.
43. 43 Richards, M, Lavigne Lissalde, G, Combescure, C, et al. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 156 (2012), 374–382.
44. 44 Kulkarni, R, Soucie, JM, Lusher, J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 15 (2009), 1281–1290.
45. 45 Carcao, MD, The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 38 (2012), 727–734.
46. 46 van den Berg, HM, De Groot, PH, Fischer, K, Phenotypic heterogeneity in severe hemophilia. J Thromb Haemost 5:suppl 1 (2007), 151–156.
47. 47 Fischer, K, Collins, P, Björkman, S, et al. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia 17 (2011), 433–438.
48. 48 Stephensen, D, Tait, RC, Brodie, N, et al. Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia 15 (2009), 1210–1214.
49. 49 Luck, JV Jr, Silva, M, Rodriguez-Merchan, EC, Ghalambor, N, Zahiri, CA, Finn, RS, Haemophilic arthropathy. J Am Acad Orthop Surg 12 (2004), 234–245.
50. 50 Valentino, LA, Blood-induced joint disease: the pathophysiology of haemophilic arthropathy. J Thromb Haemost 8 (2010), 1895–1902.
51. 51 Manco-Johnson, MJ, Abshire, TC, Shapiro, AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357 (2007), 535–544.
52. 52 Goddard, N, Joint replacement. Lee, CA, Berntorp, EE, Hoots, K, (eds.) Textbook of haemophilia, 2010, Blackwell Publishing, Chichester, UK, 176–181.
53. 53 Di Minno, MN, Ambrosino, P, Franchini, M, Coppola, A, Di Minno, G, Arthropathy in patients with moderate hemophilia A: a systematic review of the literature. Semin Thromb Hemost 39 (2013), 723–731.
54. 54 Paroskie, A, Gailani, D, DeBaun, MR, Sidonio, RF Jr, A cross-sectional study of bleeding phenotype in haemophilia A carriers. Br J Haematol 170 (2015), 223–228.
55. 55 Srivastava, A, Brewer, AK, Mauser-Bunschoten, EP, et al. Guidelines for the management of hemophilia. Haemophilia 19 (2013), e1–47.
56. 56 Fischer, K, Van der Bom, JG, Mauser-Bunschoten, EP, et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 7 (2001), 446–452.
57. 57 Berntorp, E, Astermark, J, Björkman, S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 9:suppl 1 (2003), 1–4.
58. 58 Aledort, LM, Haschmeyer, RH, Pettersson, H, the Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 236 (1994), 391–399.
59. 59 Nilsson, IM, Berntorp, E, Löfqvist, T, Pettersson, H, Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232 (1992), 25–32.
60. 60 Fischer, K, Astermark, J, van der Bom, JG, et al. Prophylaxis treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 8 (2002), 753–760.
61. 61 Tang, L, Wu, R, Sun, J, et al. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China. Haemophilia 19 (2013), 27–34.
62. 62 Gringeri, A, Lundin, B, von Mackensen, S, Mantovani, L, Mannucci, PM, A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 9 (2011), 700–710.
63. 63 Mancuso, ME, Berardinelli, L, Beretta, C, Raiteri, M, Pozzoli, E, Santagostino, E, Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica 94 (2009), 687–692.
64. 64 Collins, PW, Personalized prophylaxis. Haemophilia 18:suppl 4 (2012), 131–135.
65. 65 van Dijk, K, Fischer, K, van der Bom, JG, Grobbee, DE, van den Berg, HM, Variability in clinical phenotype of severe hemophilia: the role of the first joint bleed. Haemophilia 11 (2005), 438–443.
66. 66 Mannucci, PM, Ruggeri, ZM, Pareti, FI, Capitanio, A, 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1 (1977), 869–872.
67. 67 Mannucci, PM, Desmopressin (DDAVP) in the treatment of bleeding disorders, 2012, World Federation of Haemophilia, Montréal http://www1.wfh.org/publication/files/pdf-1131.pdf (accessed Dec 15, 2015).
68. 68 Pool, JG, Shannon, AE, Production of high-potency concentrates of antihaemophilic globulin in a closed-bag system. N Engl J Med 273 (1965), 1443–1447.
69. 69 Webster, WP, Roberts, HR, Thelin, GM, Wagner, RH, Brinkhous, KM, Clinical use of a new glycine-precipitated antihaemophilic fraction. Am J Med Sci 250 (1965), 643–651.
70. 70 Mannucci, PM, AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J Thromb Haemost 1 (2003), 2065–2069.
71. 71 Morfini, M, Innovative approach for improved rFVIII concentrate. Eur J Haematol 93 (2014), 361–368.
72. 72 Mei, B, Pan, C, Jiang, H, et al. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 116 (2010), 270–279.
73. 73 Ostergaard, H, Bjelke, JR, Hansen, L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood 118 (2011), 2333–2341.
74. 74 Tiede, A, Brand, B, Fischer, R, et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-man trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 11 (2013), 670–678.
75. 75 Coyle, TE, Reding, MT, Lin, JC, Michaels, LA, Shah, A, Powell, J, Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 12 (2014), 488–496.
76. 76 Collins, PW, Young, G, Knobe, K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 124 (2014), 3880–3886.
77. 77 Collins, PW, Moss, J, Knobe, K, Groth, A, Colberg, T, Watson, E, Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9-GP), a glycoPEGylated recombinant factor IX. J Thromb Haemost 10 (2012), 2305–2312.
78. 78 Mahlangu, J, Powell, JS, Ragni, MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 123 (2014), 317–325.
79. 79 Powell, JS, Pasi, KJ, Ragni, MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 369 (2013), 2313–2323.
80. 80 Santagostino, E, Negrier, C, Klamroth, R, et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 120 (2012), 2405–2411.
81. 81 Martinowitz, U, Lissitchkov, T, Lubetsky, A, et al. Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients. Haemophilia 21 (2015), 784–790.
82. 82 Carthew, RW, Sontheimer, EJ, Origins and mechanisms of miRNAs and siRNAs. Cell 136 (2009), 642–655.
83. 83 Keefe, AD, Pai, S, Ellington, A, Aptamers as therapeutics. Nat Rev Drug Discov 9 (2010), 537–550.
84. 84 Chowdary, P, Lethagen, S, Friedrich, U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 13 (2015), 743–754.
85. 85 Kitazawa, T, Igawa, T, Sampei, Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18 (2012), 1570–1574.
86. 86 Shima, M, Hanabusa, H, Taki, M, et al. Long-term safety and prophylactic efficacy of once weekly subcutaneous administration of ACE910, in Japanese hemophilia A patients with and without FVIII inhibitors: interim results of the extension study of a phase 1 study. J Thromb Haemost, 13(suppl S2), 2015, 6 (abstr).
87. 87 Nathwani, AC, Tuddenham, EG, Rangarajan, S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 (2011), 2357–2365.
88. 88 Nathwani, AC, Reiss, UM, Tuddenham, EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371 (2014), 1994–2004.
89. 89 High, KH, Nathwani, A, Spencer, T, Lillicrap, D, Current status of haemophilia gene therapy. Haemophilia 20:suppl 4 (2014), 43–49.
90. 90 McIntosh, J, Lenting, PJ, Rosales, C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 121 (2013), 3335–3344.
91. 91 Wang, Q, Dong, B, Firrman, J, et al. Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery. Hum Gene Ther Methods 25 (2014), 261–268.
92. 92 Matsui, H, Hegadorn, C, Ozelo, M, et al. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A. Mol Ther 19 (2011), 723–730.
93. 93 Giles, AR, Verbruggen, B, Rivard, GE, Teitel, J, Walker, I, A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 79 (1998), 872–875.
94. 94 Key, NS, Inhibitors in congenital coagulation disorders. Br J Haematol 127 (2004), 379–391.
95. 95 Darby, SC, Keeling, DM, Spooner, RJ, et al. UK Haemophilia Centre Doctors' Organisation. The incidence of FVIII and FIX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–1999. J Thromb Haemost 2 (2004), 1047–1054.
96. 96 Miller, CH, Benson, J, Ellingsen, D, et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 18 (2012), 375–382.
97. 97 Astermark, J, Oldenburg, J, Pavlova, A, Berntorp, E, Lefvert, AK, Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 107 (2006), 3167–3172.
98. 98 Astermark, J, Oldenburg, J, Carlson, J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108 (2006), 3739–3745.
99. 99 Astermark, J, Wang, X, Oldenburg, J, Berntorp, E, Lefvert, AK, Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 5 (2007), 263–265.
100. 100 Eckhardt, CL, Astermark, J, Nagelkerke, SQ, et al. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. J Thromb Haemost 12 (2014), 1294–1301.
101. 101 Aledort, LM, Di Michele, DM, Inhibitors occur more frequently in African-Americans and Latino hemophiliacs. Haemophilia, 4, 1998, 68.
102. 102 Gouw, SC, van der Bom, JG, van den Berg, HM, Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109 (2007), 4648–4654.
103. 103 Goudemand, J, Rothschild, C, Demiguel, V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107 (2006), 46–51.
104. 104 Iorio, A, Halimeh, S, Holzhauer, S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 8 (2010), 1256–1265.
105. 105 Gouw, SC, van der Bom, JG, Ljung, R, et al. Factor VIII products and inhibitor formation in severe hemophilia A. N Engl J Med 368 (2013), 231–239.
106. 106 Collins, PW, Palmer, BP, Chalmers, EA, et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe haemophilia A, 2000–2011. Blood 124 (2014), 3389–3397.
107. 107 Calvez, T, Chambost, H, Claeyssens-Donadel, S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 124 (2014), 3398–3408.
108. 108 Peyvandi, F, Mannucci, PM, Garagiola, I, et al. Source of factor VIII replacement (PLASMATIC OR RECOMBINANT) and incidence of inhibitory alloantibodies in previously untreated patients with severe hemophilia A: the multicenter randomized Sippet study. 57th Annual Meeting & Exposition of the American Society of Hematology; Orlando, FL; Dec 5–8, 2015. https://ash.confex.com/ash/2015/webprogram/Paper82866.html (accessed Nov 13, 2015).
109. 109 Fischer, K, Lassila, R, Peyvandi, F, et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 113 (2015), 968–975.
110. 110 Sharathkumar, A, Lillicrap, D, Blanchette, VS, et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb Haemost 1 (2003), 1228–1236.
111. 111 Eckhardt, CL, van Velzen, AS, Peters, M, et al. Factor VIII gene (F8) and the risk of inhibitor development in nonsevere hemophilia A. Blood 122 (2013), 1954–1962.
112. 112 Thompson, AR, Murphy, ME, Liu, M, et al. Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. Blood 90 (1997), 1902–1910.
113. 113 Peerlinck, K, Jacquemin, MG, Arnout, J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood 93 (1999), 2267–2273.
114. 114 Fischer, K, Iorio, A, Lassila, R, et al. Inhibitor development in non-severe haemophilia across Europe. Thromb Haemost 114 (2015), 670–675.
115. 115 Poon, MC, Lillicrap, D, Hensman, C, Card, R, Scully, MF, Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study. Thromb Haemost 87 (2002), 431–435.
116. 116 Eckhardt, CL, Loomans, JI, van Velzen, AS, et al. Inhibitor development and mortality in non-severe hemophilia A. J Thromb Haemost 13 (2015), 1217–1225.
117. 117 Walsh, CE, Soucie, JM, Miller, CH, United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 90 (2015), 400–405.
118. 118 Morfini, M, Haya, S, Tagariello, G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 13 (2007), 606–612.
119. 119 Monahan, PE, Baker, JR, Riske, B, Soucie, JM, Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 41:6S4 (2011), S360–S368.
120. 120 Hay, CR, DiMichele, DM, International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119 (2012), 1335–1344.
121. 121 Santagostino, E, More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance. Haemophilia 19:suppl 1 (2013), 8–11.
122. 122 Dimichele, D, The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia 15 (2009), 320–328.
123. 123 Oldenburg, J, Jiménez-Yuste, V, Peiró-Jordán, R, Aledort, LM, Santagostino, E, Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia 20 (2014), 83–91.
124. 124 Kreuz, W, Escuriola Ettingshausen, C, Vdovin, V, et al. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia, 2015, 10.1111/hae.12774 published online July 23.
125. 125 Leissinger, C, Josephson, CD, Granger, S, et al. Rituximab for treatment of inhibitors in haemophilia A: a phase II study. Thromb Hemost 112 (2014), 445–458.
126. 126 Franchini, M, Mannucci, PM, Inhibitor eradication with rituximab in haemophilia: where do we stand?. Br J Haematol 165 (2014), 600–608.
127. 127 Sjamsoedin, LJ, Heijnen, L, Mauser-Bunschoten, EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII: a double-blind clinical trial. N Engl J Med 205 (1981), 717–721.
128. 128 Key, NS, Aledort, LM, Beardsley, D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 80 (1998), 912–918.
129. 129 Astermark, J, Donfield, SM, DiMichele, DM, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 109 (2007), 546–551.
130. −1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 14 (2008), 287–294.
131. 131 Negrier, C, Goudemand, J, Sultan, Y, Bertrand, M, Rothschild, C, Lauroua, P, the members of the French FEIBA study group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 77 (1997), 1113–1119.
132. 132 Lechner, K, Nowotny, C, Krinninger, B, Zegner, M, Deutsch, E, Effect of treatment with activated prothrombin complex concentrate (FEIBA) on factor VIII-antibody level. Thromb Haemost 40 (1979), 478–485.
133. 133 Witmer, C, Young, G, Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 4 (2013), 59–72.
134. 134 Franchini, M, Coppola, A, Tagliaferri, A, Lippi, G, FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 39 (2013), 772–778.
135. 135 Schneiderman, J, Rubin, E, Nugent, DJ, Young, G, Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 13 (2007), 244–248.
136. 136 Martinowitz, U, Livnat, T, Zivelin, A, Kenet, G, Concomitant infusions of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 15 (2009), 904–910.
137. 137 Ingerslev, J, Sorensen, B, Parallel use of bypassing agents in haemophilia with inhibitors: a critical review. Br J Haematol 155 (2011), 256–262.
138. 138 Konkle, BA, Ebbesen, LS, Erhardtsen, E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 5 (2007), 1904–1913.
139. 139 Leissinger, C, Gringeri, A, Antmen, B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia patients with inhibitors. N Engl J Med 365 (2011), 1684–1692.
140. 140 Antunes, SV, Tangada, S, Stasyshyn, O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A patients with inhibitors. Haemophilia 20 (2014), 65–72.
141. 141 Ewing, N, Escuriola-Ettingshausen, C, Kreuz, W, Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia 21 (2015), 358–364.